As the drug development and diagnostic businesses of Labcorp strengthen their combined capabilities, Claudine Rigal, PharmD, Clinical Biologist, Head of Asia Pacific Laboratory Operations and Global Head of Anatomic Pathology Operations for Labcorp Drug Development, is excited about the opportunity to improve service delivery for biotech and pharma clients. We …
Enhancing the Investigator Site Experience with Electronic Query Notification and Resolution (eQuery)
Investigator sites provide an essential connection between drug development sponsors and patients in clinical trials—and play a key role in producing high-quality data. To better support a site’s day-to-day study activities and make a difference for patient care, Labcorp Central Laboratory Services (CLS) is continually evaluating current practices and implementing …
Webinar: Advancing Your Neurodegenerative Biomarker Strategy Beyond Discovery
On April 15, we hosted the virtual conference, “Advancing Your Neurodegenerative Biomarker Strategy Beyond Discovery.” For study teams working to develop treatments for patients suffering from neurodegenerative diseases, the need to leverage new techniques quickly and effectively is imperative. This topic is vital, as nearly 50 million people worldwide suffer …
Expanding clinical trial support in Europe, the Middle East and Africa with a new automated kit production line
As part of a global growth and expansion strategy, we’re announcing the spring opening of a new kit production line at our European Operations Center (EOC). Based in Mechelen, Belgium, the EOC is a multi-use facility that handles dry ice production and distribution for the EU, as well as study …
Minimal Residual Disease by Flow Cytometry: Latest Insights on Validation
Despite the development of cellular and antibody-based therapeutics that eliminate malignant cells, patients who have achieved complete remission or response may experience relapse. Increasing evidence suggests that the presence of measurable/minimal residual disease (MRD) in bone marrow (BM) tissue is one, if not the strongest, prognostic factor for disease outcome …
Six Automated Clinical Alerts You Need to Increase Efficiency in your Clinical Trials
What is an automated clinical alert? Automated clinical alerts continuously monitor study data and send alerts and notifications to clinical trial project team members based on specific study, country, site or subject performance criteria to help boost clinical study monitoring and improve quality management.
Decentralized Clinical Trials (DCT) Monthly Blog – February 2021
Most of our blogs focus on interesting things we hear from sponsors, new company developments, or interesting challenges we encounter as we partner with sponsors. This month, however, we want to take a look at it from the patient perspective. The changes of the past year have resulted in a …
Innovation in Plasma Cell Enrichment for Multiple Myeloma Studies
Syndecan-1 (SDC1), also known as CD138, is a well-known and specific plasma cell marker that is highly expressed on the surface of multiple myeloma plasma cells. As it can be a challenge detecting the small number of malignant plasma cells within the large proportion of cells obtained from a bone …
Decentralized Clinical Trials (DCT) Monthly Blog – January 2021
What’s Next? In the aftermath of a turbulent 2020, in which the overall industry perception of the decentralized clinical trial (DCT) approach transitioned from being “promising but still largely experimental” to “a new-normal paradigm for the industry to adopt,” we have been considering “what’s next?”
Centralized Multiple Myeloma Service Delivers on a Global Scale
As the volume of multiple myeloma clinical trials continues to grow, additional tests are being validated in an effort to benefit patients who typically have a five-year survival rate. These dynamics are driving strategies to address variability in testing procedures and data analysis. We recently met with our dedicated Multiple …